Skip to main content

flutamide

Generic: FLUTAMIDE·Brand: EULEXIN, Eulexin, FLUTAMIDE

flutamide: 5 clinical trials tracked.

flutamide evidence translation

What we can confirm

5 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about flutamide, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 2 study sponsors
Clinical Trials (5)

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

NCT05050084·Phase 3·CGON
Active, not recruiting

Primary endpoint: Distant metastasis (DM) (De-intensification study)

InterventionalRandomizedopen2,050 targetStarted 2021-12Completion 2026-1150 sites · United StatesNRG Oncology

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

NCT04513717·Phase 3·CGON
Active, not recruiting

Primary endpoint: Metastasis-free survival (MFS)

InterventionalRandomizedopen2,753 enrolledStarted 2021-01Completion 2038-1250 sites · United StatesNRG Oncology

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

NCT03070886·Phase 2/Phase 3·CGON
Completed

Primary endpoint: Freedom from progression (FFP) (Phase II)

InterventionalRandomizedopen612 enrolledStarted 2017-04Completion 2025-1050 sites · United StatesNRG Oncology

A Randomized Study of Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone in Patients With Prostate Cancer Who Have PSA Progression After Prostatectomy and/or Radiotherapy

NCT01786265·Phase 2·SPRY
Active, not recruiting

Primary endpoint: Prostate-specific antigen (PSA) free survival (PSA < 0.1 ng/ml)

InterventionalRandomizedopen310 targetStarted 2013-02Completion 2027-021 site · United StatesM.D. Anderson Cancer Center

A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer

NCT00936390·Phase 3·CGON
Completed

Primary endpoint: Percentage of Participants Alive (Overall Survival)

InterventionalRandomizedopen1,538 enrolledStarted 2009-09Completion 2025-0950 sites · United StatesRadiation Therapy Oncology Group